JP2014530360A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530360A5 JP2014530360A5 JP2014533883A JP2014533883A JP2014530360A5 JP 2014530360 A5 JP2014530360 A5 JP 2014530360A5 JP 2014533883 A JP2014533883 A JP 2014533883A JP 2014533883 A JP2014533883 A JP 2014533883A JP 2014530360 A5 JP2014530360 A5 JP 2014530360A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- deposit
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 239000013612 plasmid Substances 0.000 claims 12
- 238000003745 diagnosis Methods 0.000 claims 10
- 238000003556 assay Methods 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 5
- 102000028589 Rab4 Human genes 0.000 claims 3
- 102000028677 Rab9 Human genes 0.000 claims 3
- 108050007276 Rab9 Proteins 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 108010044923 rab4 GTP-Binding Proteins Proteins 0.000 claims 3
- 101100328887 Caenorhabditis elegans col-34 gene Proteins 0.000 claims 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102100034485 Ras-related protein Rab-2A Human genes 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 230000005986 heart dysfunction Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 108010067765 rab2 GTP Binding protein Proteins 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161545042P | 2011-10-07 | 2011-10-07 | |
| US61/545,042 | 2011-10-07 | ||
| US201261624943P | 2012-04-16 | 2012-04-16 | |
| US61/624,943 | 2012-04-16 | ||
| US201261668841P | 2012-07-06 | 2012-07-06 | |
| US61/668,841 | 2012-07-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014530360A JP2014530360A (ja) | 2014-11-17 |
| JP2014530360A5 true JP2014530360A5 (enExample) | 2015-11-12 |
Family
ID=46980957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014533883A Pending JP2014530360A (ja) | 2011-10-07 | 2012-10-04 | 診断マーカーとしてのｏｘＭＩＦ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9958456B2 (enExample) |
| EP (1) | EP2748613B1 (enExample) |
| JP (1) | JP2014530360A (enExample) |
| AR (1) | AR088244A1 (enExample) |
| AU (1) | AU2012320597C1 (enExample) |
| HK (1) | HK1198591A1 (enExample) |
| TW (1) | TW201321408A (enExample) |
| WO (1) | WO2013050453A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013050453A1 (en) | 2011-10-07 | 2013-04-11 | Baxter Healthcare S.A. | Oxmif as a diagnostic marker |
| AU2013202693B2 (en) * | 2012-04-16 | 2015-01-22 | Baxalta GmbH | Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics |
| KR20150029017A (ko) * | 2012-07-10 | 2015-03-17 | 박스터 헬쓰케어 에스에이 | 항-mif 면역조직화학 |
| US9536304B2 (en) * | 2013-08-30 | 2017-01-03 | Dairy Quality Inc. | Determining pathogens based on an image of somatic cells in a fluid sample |
| JP6615753B2 (ja) * | 2013-10-04 | 2019-12-04 | レジニアス リミテッド | 細胞療法のためのバイオマーカー |
| AU2015206178A1 (en) * | 2014-01-03 | 2016-07-07 | Baxalta GmbH | Anti-MIF immunohistochemistry |
| WO2016026956A1 (en) * | 2014-08-22 | 2016-02-25 | Baxalta GmbH | Detection of cho-mif contaminations |
| JP2021526820A (ja) * | 2018-06-07 | 2021-10-11 | オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 癌治療のための抗ｏｘＭＩＦ／抗ＣＤ３抗体 |
| CN115943160A (zh) * | 2019-12-06 | 2023-04-07 | 翁科奥内研发有限责任公司 | 抗oxMIF/抗CD3双特异性抗体构建体 |
| WO2022167474A1 (en) * | 2021-02-03 | 2022-08-11 | Oncoone Research & Development Gmbh | ANTI-oxMIF RADIOIMMUNOCONJUGATE |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4299814A (en) | 1979-05-25 | 1981-11-10 | Monsanto Company | Radioimmunoassay of MIF |
| JPH0672158B2 (ja) * | 1984-05-24 | 1994-09-14 | チバ−ガイギ− アクチエンゲゼルシヤフト | 精製されたヒトマクロファージ遊走阻止因子 |
| US4946674A (en) | 1984-10-05 | 1990-08-07 | Bioferon Biochemische Substanzen Gmbh & Co. | Process for treatment of rheumatic diseases |
| US4708937A (en) | 1984-10-15 | 1987-11-24 | Brigham & Women's Hospital | Purified migration inhibitory factor also having colony stimulating factor activity |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE3789413T2 (de) | 1986-10-03 | 1994-07-28 | Ciba Geigy Ag | Lymphokin-ähnliche Peptide. |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1990011301A1 (en) | 1989-03-17 | 1990-10-04 | Genetics Institute, Inc. | Human macrophage migration inhibitory factor |
| US5785054A (en) | 1989-06-06 | 1998-07-28 | Kelly; Patrick D. | Genital lubricant with zinc salt, labelled as anti-viral agent |
| GB8915414D0 (en) | 1989-07-05 | 1989-08-23 | Ciba Geigy | Novel cytokines |
| AU634314B2 (en) | 1989-11-13 | 1993-02-18 | Green Cross Corporation, The | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen |
| US5227459A (en) | 1990-05-18 | 1993-07-13 | Yale University | Synthetic melanin |
| US5786168A (en) | 1990-06-04 | 1998-07-28 | Kirin Beer Kabushiki Kaisha | Method for recombinant production of antigen non-specific glycosylation inhibiting factor (GIF) |
| US5585479A (en) | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
| US6080407A (en) | 1993-05-17 | 2000-06-27 | The Picower Institute For Medical Research | Diagnostic assays for MIF |
| US6774227B1 (en) | 1993-05-17 | 2004-08-10 | Cytokine Pharmasciences, Inc. | Therapeutic uses of factors which inhibit or neutralize MIF activity |
| WO1994026307A1 (en) | 1993-05-17 | 1994-11-24 | The Picower Institute For Medical Research | Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity |
| US5559028A (en) | 1993-05-19 | 1996-09-24 | Antigen Express, Inc. | Methods of enhancing or antigen presentation to T cells inhibiting |
| AU7394294A (en) | 1994-05-16 | 1995-12-05 | Human Genome Sciences, Inc. | Macrophage migration inhibitory factor-3 |
| US5747023A (en) | 1994-07-01 | 1998-05-05 | Genentech, Inc. | Cancer therapy using lymphotoxin |
| SI9400363A (en) | 1994-09-19 | 1996-08-31 | Mozetic Francky Bojana | Human macrophage migration inhibitory factor of nonlymphoid origin, expression of mif in e. coli and purification of recombinant protein |
| AU4365796A (en) | 1994-11-16 | 1996-06-06 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor |
| JPH0977799A (ja) | 1995-09-13 | 1997-03-25 | Sapporo Immuno Diagnostic Lab:Kk | ヒト−マクロファージ遊走阻止因子（ヒト−ｍｉｆ）に対するモノクローナル抗体および該抗体を産生するハイブリドーマ |
| WO1997025344A1 (en) | 1996-01-03 | 1997-07-17 | The Australian National University | Clip analogues and autoimmune disease |
| US6420188B1 (en) | 1996-02-16 | 2002-07-16 | The Picower Institute For Medical Research | Screening assay for the identification of inhibitors for macrophage migration inhibitory factor |
| US6492428B1 (en) | 2000-07-26 | 2002-12-10 | The Picower Institute For Medical Research | Compounds having MIF antagonist activity |
| US5726020A (en) | 1996-06-11 | 1998-03-10 | University Of Massachusetts | Inhibition of II synthesis |
| US6297253B1 (en) | 1996-10-15 | 2001-10-02 | The Picower Institute For Medical Research | Compounds and methods of use to treat infectious diseases |
| US6395276B1 (en) | 1997-05-02 | 2002-05-28 | Immunomedics, Inc. | Immunotoxins directed against malignant cells |
| AU6336398A (en) | 1997-02-24 | 1998-09-09 | Johns Hopkins University, The | Immunomodulatory polypeptides derived from the invariant chain of mhc class ii |
| CA2205680A1 (en) | 1997-05-16 | 1998-11-16 | The University Of Western Ontario | Clip immunomodulatory peptide |
| US6011005A (en) | 1997-09-18 | 2000-01-04 | The Picower Institute For Medical Research | Prevention of pregnancy miscarriages |
| AU747767B2 (en) | 1997-11-05 | 2002-05-23 | University Of Southern California | Use of cytokines and mitogens to inhibit pathological immune responses |
| RU2236251C2 (ru) | 1999-02-12 | 2004-09-20 | Дзе Скриппс Рисерч Инститьют | Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии |
| AU1235601A (en) | 1999-10-29 | 2001-05-14 | Cytokine Pharmasciences, Inc. | Compounds having mif antagonist activity |
| US6268151B1 (en) | 2000-01-20 | 2001-07-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of macrophage migration inhibitory factor expression |
| AU2001238677A1 (en) | 2000-02-28 | 2001-09-12 | Idec Pharmaceuticals Corporation | Method for preparing anti-mif antibodies |
| CA2455915C (en) | 2001-03-29 | 2013-05-14 | Cytokine Pharmasciences, Inc. | Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| US7205107B2 (en) | 2001-12-21 | 2007-04-17 | Cytokine Pharmasciences, Inc. | Macrophage migration inhibitory factor (MIF) promoter polymorphism in inflammatory disease |
| US20050202010A1 (en) | 2003-08-29 | 2005-09-15 | Giroir Brett P. | Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor |
| US8883160B2 (en) | 2004-02-13 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for therapeutic and diagnostic use |
| CN105709237A (zh) | 2005-12-16 | 2016-06-29 | Ibc 医药公司 | 基于免疫球蛋白的多价生物活性装配体 |
| CN100457895C (zh) | 2006-05-24 | 2009-02-04 | 中国科学院生物物理研究所 | 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用 |
| ES2531629T3 (es) * | 2008-01-04 | 2015-03-18 | Baxter International Inc. | Anticuerpos anti-MIF |
| EP2079202A1 (en) * | 2008-01-08 | 2009-07-15 | NEC Corporation | Method for optimizing the triggering of the transmission of buffer status reporting (BSR) information |
| JP5786204B2 (ja) | 2010-01-19 | 2015-09-30 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | インスリン様増殖因子ｉ型受容体（ｉｇｆ−１ｒ）を標的とする新規クラスの単一特異性ヒト化抗体および二重特異性ヒト化抗体 |
| AU2012327159B2 (en) | 2011-10-07 | 2015-03-26 | Baxalta GmbH | Characterization of CHO-MIF gene and protein, and use thereof |
| WO2013050453A1 (en) | 2011-10-07 | 2013-04-11 | Baxter Healthcare S.A. | Oxmif as a diagnostic marker |
-
2012
- 2012-10-04 WO PCT/EP2012/069598 patent/WO2013050453A1/en not_active Ceased
- 2012-10-04 JP JP2014533883A patent/JP2014530360A/ja active Pending
- 2012-10-04 EP EP12769097.2A patent/EP2748613B1/en active Active
- 2012-10-04 HK HK14112074.8A patent/HK1198591A1/xx unknown
- 2012-10-04 US US14/350,186 patent/US9958456B2/en active Active
- 2012-10-04 AU AU2012320597A patent/AU2012320597C1/en active Active
- 2012-10-05 TW TW101137028A patent/TW201321408A/zh unknown
- 2012-10-05 AR ARP120103713A patent/AR088244A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530360A5 (enExample) | ||
| WO2013050453A4 (en) | Oxmif as a diagnostic marker | |
| Wu et al. | Magnetic-nanosensor-based virus and pathogen detection strategies before and during COVID-19 | |
| Lu et al. | Gut microbiome phenotypes driven by host genetics affect arsenic metabolism | |
| Ronvaux et al. | Liquid biopsy in glioblastoma | |
| Marjomäki et al. | Site-specific targeting of enterovirus capsid by functionalized monodisperse gold nanoclusters | |
| HRP20191013T1 (hr) | Protutijela na il-6 i njihova uporaba | |
| JP2015530971A5 (enExample) | ||
| Yousef et al. | (E)-N-(3-(1-(2-(4-(2, 2, 2-Trifluoroacetamido) benzoyl) hydrazono) ethyl) phenyl) nicotinamide: a novel pyridine derivative for inhibiting vascular endothelial growth factor receptor-2: synthesis, computational, and anticancer studies | |
| Tshala-Katumbay et al. | Cassava food toxins, konzo disease, and neurodegeneration in sub-Sahara Africans | |
| JP2006520781A5 (enExample) | ||
| JP2011217747A5 (enExample) | ||
| RU2013153592A (ru) | Анти-mif антитела | |
| JP2014076062A5 (enExample) | ||
| JP2013531655A5 (enExample) | ||
| JP2016509585A5 (enExample) | ||
| Rouah-Martin et al. | Aptamer-based molecular recognition of lysergamine, metergoline and small ergot alkaloids | |
| JP2017522886A5 (enExample) | ||
| JP2015502547A5 (enExample) | ||
| Greuter et al. | Typical pediatric brain tumors occurring in adults—differences in management and outcome | |
| Mori et al. | Gut microbial signatures in sporadic and hereditary colorectal cancer | |
| JP2014502848A5 (enExample) | ||
| JP2017538412A5 (enExample) | ||
| JP2012131808A5 (enExample) | ||
| Guk et al. | Development of A4 antibody for detection of neuraminidase I223R/H275Y-associated antiviral multidrug-resistant influenza virus |